Tag - SRZN

Developments

FDA clears IND application for Surrozen’s SZN-8141 in DME

Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development. SZN...

October 2, 2026

Markets

Stifel starts Surrozen at buy; PT $19

Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...

September 7, 2021

Tag - SRZN

FDA clears IND application for Surrozen’s SZN-8141 in DME

Stifel starts Surrozen at buy; PT $19

Subscribe